1. Deciphering Mesenchymal Drivers of Human Dupuytren's Disease at Single-Cell Level.
- Author
-
Dobie R, West CC, Henderson BEP, Wilson-Kanamori JR, Markose D, Kitto LJ, Portman JR, Beltran M, Sohrabi S, Akram AR, Ramachandran P, Yong LY, Davidson D, and Henderson NC
- Subjects
- Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cell Differentiation, Cell Proliferation, Cells, Cultured, Endopeptidases metabolism, Fibrosis genetics, Gene Expression Profiling, Gene Knockdown Techniques, Humans, Membrane Glycoproteins metabolism, Membrane Proteins metabolism, Sequence Analysis, RNA, Single-Cell Analysis, TWEAK Receptor genetics, TWEAK Receptor metabolism, Dermis physiology, Dupuytren Contracture genetics, Fibroblasts physiology, Mesenchymal Stem Cells physiology, Myofibrils pathology
- Abstract
Dupuytren's disease (DD) is a common, progressive fibroproliferative disease affecting the palmar fascia of the hands, causing fingers to irreversibly flex toward the palm with significant loss of function. Surgical treatments are limited; therefore, effective new therapies for DD are urgently required. To identify the key cellular and molecular pathways driving DD, we employed single-cell RNA sequencing, profiling the transcriptomes of 35,250 human single cells from DD, nonpathogenic fascia, and healthy dermis. We identify a DD-specific population of pathogenic PDPN
+ /FAP+ mesenchymal cells displaying an elevated expression of fibrillar collagens and profibrogenic genes. In silico trajectory analysis reveals resident fibroblasts to be the source of this pathogenic population. To resolve the processes governing DD progression, genes differentially expressed during fibroblast differentiation were identified, including upregulated TNFRSF12A and transcription factor SCX. Knockdown of SCX and blockade of TNFRSF12A inhibited the proliferation and altered the profibrotic gene expression of cultured human FAP+ mesenchymal cells, demonstrating a functional role for these genes in DD. The power of single-cell RNA sequencing is utilized to identify the major pathogenic mesenchymal subpopulations driving DD and the key molecular pathways regulating the DD-specific myofibroblast phenotype. Using this precision medicine approach, inhibition of TNFRSF12A has shown potential clinical utility in the treatment of DD., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF